By Supurna Chowdhury, Quality Assurance Manager, and Erik Amundrud, Manufacturing Manager, MilliporeSigma
Viral vectors, engineered viruses used to transport genetic material into cells, are in high demand in today’s therapeutic industry. The industry has an important responsibility to efficiently produce compliant viral vectors to deliver life-saving therapies. Compounding this is the accelerated pathway to commercialization that many viral vector-based therapies follow, putting even more pressure on developers to identify competent manufacturing partners that can consistently provide high-quality viral vectors. With these challenges in mind, it is critical to vet not just the expertise available at a CDMO, but also the effectiveness of their facility design to reduce risk and meet scale-up needs. An experienced CDMO with an efficiently and compliantly designed facility can simplify the regulatory approval and commercialization process of your product, allowing you to meet your aggressive timelines to market entry and improving your advantage in an increasingly competitive market.